Who Paid My Doc
Encelto
Drug idiopathic macular telangiectasia type 2
NDC 82958-501-01
General payments
$325,595
Research payments
$328,531
Through program year 2025, $325,595 in general payments and $328,531 in research payments were reported against Encelto (idiopathic macular telangiectasia type 2).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $325,595 | 59 |
| 2025 | Research | $328,531 | 45 |
Breakdown
The top 5 of 20 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 10 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
59 general · 45 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.